MarketCapExport financials
OncoCyte Corporation (OCX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
OncoCyte Corporation Income Statement 2025-2011 | OCX
Brief overview of profit and loss at OncoCyte Corporation
The overview follows changes across a five-year period. According to figures from OncoCyte Corporation, revenue changed from 1.2 million dollars to 4.1 million dollars over five years. Overall revenue changed by +233.5%, equal to an annualized rate of about 27.2%. Sales grew at a rate typical of a strong expansion phase.
Gross profit was −$639 thousand at the start and $2.3 million at the end of the period (+459.6%). The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from −52.5% to 56.7%. A wider margin shows that the economics of the core business improved.
EBITDA was −$31.8 million at the beginning and −$48.9 million at the end of the period (−53.7%). EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −2617% to −1206.6%. The business generated more EBITDA from each unit of revenue.
Across the five years, the net result shifted from −$29.9 million to −$50.2 thousand. The loss narrowed, although sustainable profitability has not yet returned.
Overall conclusion
The results present an uneven picture without one dominant signal. The constructive conclusion rests on higher operating efficiency, improving gross profitability and sales growth. The weaker side of the profile includes a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement OncoCyte Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | - | 1.94 M | 130 K | 263 M | 137 M | 197 M | 122 M | 155 M | 87.2 M | - | - | - | - |
Shares |
30.5 M | 13.1 M | 7.65 M | 5.54 M | 88.9 K | 51.3 M | 51.3 M | 37.8 M | 30.2 M | 26.5 M | 21 M | - | - | - | - |
Historical Prices |
- | - | - | 0.35 | 1.46 | 4.92 | 2.15 | 3.32 | 3.3 | 5.65 | 3.84 | - | - | - | - |
Net Income |
-50.2 K | -60.7 K | -27.8 K | -72.9 M | -64.1 M | -29.9 M | -22.4 M | -15.8 M | -19.4 M | -11.2 M | -8.74 M | -4.99 M | -3.5 M | - | - |
Revenue |
4.06 M | 1.88 M | 1.5 M | 958 K | 2.2 M | 1.22 M | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
1.75 M | 1.05 M | 1 M | 880 K | 697 K | 1.86 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
2.3 M | 740 K | 413 K | -18 K | 1.42 M | -639 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-51.1 M | -61 M | -25.1 M | -18 M | -53.7 M | -29.7 M | -22.2 M | -15.2 M | -18.8 M | -11.1 M | -8.72 M | -4.97 M | - | - | - |
Interest Expense |
1.01 M | 462 K | 394 K | -61 K | -37 K | 27 K | -3 K | 91 K | -309 K | - | 18 K | - | - | - | - |
EBITDA |
-48.9 M | -59.5 M | -23.5 M | -16.5 M | -52.9 M | -31.8 M | -21.9 M | -14.6 M | -18.3 M | -10.8 M | -8.44 M | -4.69 M | -3.22 M | - | - |
Operating Expenses |
53.4 M | 61.8 M | 25.5 M | 18 M | 55.1 M | 33.1 M | 22 M | 15 M | 19 M | 11 M | 9 M | 5 M | 3 M | - | - |
General and Administrative Expenses |
10.6 M | 10.2 M | 11.2 M | 21.9 M | 22.3 M | 16.8 M | 13.3 M | 7.01 M | 9.23 M | 5.46 M | 4.19 M | 1.01 M | 552 K | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement OncoCyte Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
32 M | 34.5 M | - | 32 M | 32 M | 25.7 M | 17.5 M | 13.7 M | 12.9 M | 8.26 M | 8.26 M | 8.26 M | 8.09 M | 5.96 M | 5.93 M | 5.93 K | 5.65 K | 92.2 M | 92.2 M | 91.5 M | 89.8 M | 82.1 M | 69.1 M | 67.2 M | 65.8 M | 61.5 M | 57 M | 52 K | 52 K | 46.6 K | 40.7 M | 40.2 M | 38.7 M | 31.7 M | 31.5 M | 30.9 K | 29.4 M | 29 M | 28.7 M | 26.6 M | 25.4 M | 25.4 M | 25.4 M | 21 M | 21.2 M | 18.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.74 M | -4.29 M | - | -10.9 M | -9.74 M | -6.67 M | - | -13.5 M | -4.53 M | -9.13 M | - | -6.49 M | -8.33 M | 3.03 M | - | -9.33 M | -8.3 M | -10.3 M | -35.9 M | -13.8 M | -10.5 M | -3.92 M | -6.31 M | -6.78 M | -9.11 M | -7.73 M | - | -5.22 M | -5.38 M | -3.86 M | - | -2.97 M | -4.5 M | -3.78 M | - | -6.91 M | -3.8 M | -4.7 M | - | -2.6 M | -2.54 M | -2.93 M | - | -2.42 M | -1.41 M | -1.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
518 K | 32 K | - | 260 K | 518 K | 2.14 M | - | 115 K | 104 K | 176 K | - | 429 K | 463 K | 297 K | - | 67 K | 237 K | 1.42 M | 3.59 M | 984 K | 2.03 M | 1.12 M | 503 K | 555 K | 143 K | 16 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
180 K | 17 K | - | 121 K | 168 K | 806 K | - | 43 K | 32 K | 252 K | - | 159 K | 169 K | 265 K | - | 314 K | 183 K | 1.02 M | 2.22 M | 860 K | 1.35 M | 738 K | 716 K | 601 K | 365 K | 173 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
338 K | 15 K | - | 139 K | 350 K | 1.32 M | - | 50 K | 50 K | -98 K | - | 248 K | 272 K | 10 K | - | -269 K | 31 K | -533 K | - | -866 K | -394 K | 79 K | - | -46 K | -222 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.84 M | -4.41 M | - | -11 M | -9.84 M | -6.8 M | - | -13.5 M | -4.63 M | -9.27 M | - | -6.51 M | -8.29 M | 5.85 M | - | -1.71 M | -1.63 M | -9.9 M | -35.7 M | -13.6 M | -13.6 M | -11.4 M | -6.27 M | -6.24 M | -8.77 M | -8.43 M | - | -5.26 M | -5.46 M | -4 M | - | -3.02 M | -4.23 M | -3.91 M | - | -6.84 M | -3.59 M | -4.53 M | - | -2.58 M | -2.53 M | -2.93 M | - | -2.41 M | -1.4 M | -1.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-25 K | 146 K | - | 223 K | 125 K | 157 K | - | 53 K | 110 K | 153 K | - | 127 K | -1 K | -1 K | - | 62 K | 278 K | -36 K | - | -8 K | 16 K | 2 K | - | 1 K | 20 K | 8 K | - | -25 K | -25 K | -26 K | - | -4 K | -2 K | -2 K | - | -71 K | -65 K | -159 K | - | -13 K | -11 K | - | - | -1 K | -6 K | -2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-9.84 M | -3.78 M | - | -10.5 M | -9.28 M | -6.31 M | - | -13.2 M | -4.31 M | -8.95 M | - | -6.11 M | -7.86 M | 6.3 M | - | -1.32 M | -1.24 M | -9.61 M | -35.7 M | -13.3 M | -13.4 M | -11.1 M | -6.27 M | -6.18 M | -8.7 M | -8.37 M | - | -5.17 M | -5.38 M | -3.89 M | - | -2.91 M | -4.12 M | -3.8 M | - | -6.74 M | -3.51 M | -4.46 M | - | -2.53 M | -2.48 M | -2.92 M | - | -2.37 M | -1.38 M | -1.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
10.2 M | 4.43 M | - | 11.2 M | 10.2 M | 8.12 M | - | 13.6 M | 4.68 M | 9.17 M | - | 6.76 M | 8.57 M | -5.84 M | - | 1.44 M | 1.66 M | 9.36 M | - | 12.7 M | 13.2 M | 11.4 M | - | 6.2 M | 8.55 M | 8.45 M | - | 5.26 M | 5.46 M | 4 M | - | 3.02 M | 4.23 M | 3.91 M | - | 6.84 M | 3.59 M | 4.53 M | - | 2.58 M | 2.53 M | 2.93 M | - | 2.41 M | 1.4 M | 1.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.65 M | 2.99 M | - | 2.54 M | 2.65 M | 3.12 M | - | 2.56 M | 2.41 M | 2.67 M | - | 2.49 M | 3.53 M | 3.41 M | - | 5.7 M | 5.44 M | 5.65 M | 4.14 M | 5.5 M | 7.93 M | 4.76 M | 3.41 M | 5 M | 3.76 M | 4.62 M | - | 3 M | 3.64 M | 2.45 M | - | 1.31 M | 1.34 M | 1.79 M | - | 4.29 M | 1.12 M | 2.04 M | - | 1.06 M | 1.07 M | 1.02 M | - | 1.31 M | 519 K | 250 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company OncoCyte Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Danmark
Schweiz
Britain
Israel
Niderland
Cayman-islands
India
